Biofrontera Inc (BFRI)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $10.40M
Last updated: Nov 17, 2026 at 4:35 PM ET
Biofrontera Inc (BFRI) Statistics
Biofrontera (BFRI) has a market cap of $10.40M and an enterprise value of $11.93M. Its share count is up 41.79% from a year earlier. Revenue grew 29.85% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 14.72% above the market cap, as debt exceeds cash.
| Market Cap | $10.40M |
|---|---|
| Enterprise Value | $11.93M |
| Latest price (Nov 17, 2026) | $0.59 |
Key Dates
The next earnings report is expected on Mar 16, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 16, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 0.2x. Its year-end P/S ranged from 0.1x to 0.1x from 2023 to 2025.
| P/S Ratio | 0.2x |
|---|---|
| Forward P/S | 0.2x |
Price Statistics
The stock is down 27.44% over 52 weeks and trades 39.80% below its 50-day average.
| Beta (1Y) | 1.96 |
|---|---|
| 52-Week Change | -27.44% |
| 1-Month Change | -26.36% |
| 3-Month Change | -58.22% |
| 6-Month Change | -26.39% |
| 5-Year Change | -99.01% |
| Total Return (1Y) | -27.44% |
| Total Return (3Y CAGR) | -45.27% |
| Total Return (5Y CAGR) | -58.96% |
| Max Drawdown (1Y) | -64.60% |
| Max Drawdown (3Y) | -85.40% |
| Sharpe Ratio (1Y) | -0.37 |
| Correlation with SPY (1Y) | 0.31 |
| 50-Day Average | $0.98 |
| 200-Day Average | $1.03 |
| 52-Week Range | $0.56 to $1.66 |
| RSI (14 Days) | 29.9 |
| Average Volume (20 Days) | 201.08K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.78x current liabilities.
| Current Ratio | 0.78x |
|---|---|
| Quick Ratio | 0.66x |
Returns and Efficiency
Return on invested capital is -124.63% over the last 12 months.
| Return on Assets (ROA) | -28.60% |
|---|---|
| Return on Invested Capital (ROIC) | -124.63% |
| Return on Capital Employed (ROCE) | -77.69% |
| ROA (5Y Average) | -52.29% |
| Asset Turnover | 2.62x |
| Inventory Turnover | 6.97x |
| Receivables Turnover | 9.34x |
| Cash Conversion Cycle | -350 days |
Scores
BFRI has an Altman Z-Score of -7.65, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -7.65 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $48.26M over the last 12 months.
| Revenue | $48.26M |
|---|---|
| Revenue Growth (YoY) | +29.85% |
| Gross Profit | $38.40M |
| Operating Income | -$6.79M |
| Pretax Income | -$6.11M |
| Net Income | -$6.14M |
| EBITDA | -$4.95M |
| EBIT | -$5.62M |
| Reported EPS (TTM) | -$0.38 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $3.22M |
|---|---|
| Total Debt | $4.75M |
| Net Debt | $1.53M |
| Net Debt Per Share | $0.10 |
| Working Capital | -$3.13M |
| Shareholder Equity | -$243.00K |
| Tangible Book Value | -$2.77M |
| Total Assets | $21.47M |
| Total Liabilities | $21.71M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$5.54M |
|---|---|
| FCF Per Share | -$0.37 |
| Depreciation and Amortization | $662.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -14.06%, against a 5-year average of -61.85%.
| Gross Margin | 79.58% |
|---|---|
| Operating Margin | -14.06% |
| Pretax Margin | -12.67% |
| Net Margin | -12.72% |
| EBITDA Margin | -10.27% |
| EBIT Margin | -11.64% |
| Gross Margin (5Y Average) | 74.53% |
| Operating Margin (5Y Average) | -61.85% |
| Net Margin (5Y Average) | -58.13% |
Growth
Revenue grew 13.30% a year over 3 years.
| Revenue Growth (3Y CAGR) | +13.30% |
|---|---|
| Revenue Growth (5Y CAGR) | +17.21% |
| Book Value Per Share Growth (2Y CAGR) | -36.61% |
| Tangible Book Per Share Growth (2Y CAGR) | -18.46% |
Stock Splits
The last split was a 1-for-20 reverse split on Jul 5, 2023.
| Last Split Date | Jul 5, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:20 |
Peer Position
Against 4 similar companies, BFRI has the 4th highest P/S.
P/S RatioPeer median 1.1x
ROICPeer median -18.14%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +10.01%
| P/S Ratio | 0.2x vs 1.1x median |
|---|---|
| ROIC | -124.63% vs -18.14% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +29.85% vs +10.01% median |
Analyst Forecast
Consensus estimates put revenue growth at 13.23% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +13.23% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About BFRI
What is BFRI's market cap?
Biofrontera has a market cap of $10.40M. Its enterprise value, which adds debt and subtracts cash, is $11.93M.
How many shares of BFRI are outstanding?
Biofrontera has 15.28M shares outstanding. The count is up 41.79% from a year earlier.
Does BFRI pay a dividend?
No. Biofrontera does not pay a dividend.
How much debt does BFRI have?
Biofrontera has $4.75M of total debt and $3.22M of cash and equivalents, a net debt position of $1.53M.
BFRI pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors, Government Contracts